Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Effect of post-transplant cyclophosphamide on outcomes in stem cell transplant recipients with myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

HJHyejeong JangAKAndrew KinLALois Ayash

Discussion

Loading...

Member takes

Overview

Analysis shows higher mortality in HLA-mismatched transplant recipients with myelofibrosis, highlighting GVHD risks and challenges.

Key Points

  • HLA-mismatched donors had a significantly higher risk of mortality and relapse compared to matched donors.
  • Overall survival for patients was 12.5 years with a median follow-up of over 5 years.
  • Assessment of associations between transplantation variables showed significant impacts on GVHD and survival rates.
  • Findings indicate that patients with low performance status have a higher risk of acute graft-versus-host disease.

Cite This Study

Jang et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd03https://doi.org/10.1182/blood-2025-7832
View Full Paper
Ask AI
Bookmark
Share